Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Lung cancer and malignant melanoma are major healthcare ... PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer.

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... in a Chinese PD-L1-positive non-small cell lung cancer (NSCLC) population. That led some market ...

Tim Story, a Mississippi football coach, was given months to live after late-stage colon cancer. He enrolled in a clinical ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

A longtime East Texas police chief is calling it a day, so to speak, and moving on to a more important job: beating cancer.

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Cancer-associated fibroblasts (CAFs) play an important role in metastatic melanoma, and an enhanced understanding of that role could lead to important new therapeutic pathways, according to a new ...